See more : Guaranty Corporation (GRTYA) Income Statement Analysis – Financial Results
Complete financial analysis of Kiromic BioPharma, Inc. (KRBP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Kiromic BioPharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- H2O Innovation Inc. (HEOFF) Income Statement Analysis – Financial Results
- GreenPower Motor Company Inc. (GPV.V) Income Statement Analysis – Financial Results
- Lux Amber, Corp. (LXAM) Income Statement Analysis – Financial Results
- Fair Oaks Income Limited (FAIR.L) Income Statement Analysis – Financial Results
- Bank of India Limited (BANKINDIA.BO) Income Statement Analysis – Financial Results
Kiromic BioPharma, Inc. (KRBP)
About Kiromic BioPharma, Inc.
Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell to target solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; and ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L. The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.80M | 2.07M | 469.80K | 200.00K | 87.50K | 80.90K |
| Gross Profit | -2.80M | -2.07M | -469.80K | -200.00K | -87.50K | -80.90K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 9.62M | 13.92M | 11.37M | 5.05M | 1.20M | 1.42M |
| General & Administrative | 10.31M | 17.19M | 13.94M | 14.14M | 2.50M | 1.76M |
| Selling & Marketing | -2.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.52M | 17.19M | 13.94M | 14.14M | 2.50M | 1.76M |
| Other Expenses | 0.00 | 0.00 | 53.40K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 17.14M | 31.11M | 25.31M | 19.20M | 3.71M | 3.18M |
| Cost & Expenses | 19.94M | 31.11M | 25.31M | 19.20M | 3.71M | 3.18M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | -1.85M | 166.50K | 12.20K | 3.30K | 22.50K | 633.10K |
| Depreciation & Amortization | 2.80M | 2.07M | 469.80K | 200.00K | 87.50K | 80.90K |
| EBITDA | -16.30M | -32.50M | -25.74M | -19.00M | -3.62M | -3.10M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -19.94M | -31.11M | -25.74M | -19.20M | -3.71M | -3.18M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.01M | -3.62M | 147.00K | -3.30K | -22.50K | -633.10K |
| Income Before Tax | -20.95M | -34.73M | -25.59M | -19.20M | -3.73M | -3.82M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 3.45M | 65.60K | 3.30K | 22.50K | -80.24K |
| Net Income | -21.29M | -38.18M | -25.65M | -19.20M | -3.75M | -3.82M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -21.41 | -70.12 | -67.40 | -79.08 | -29.00 | -32.40 |
| EPS Diluted | -21.41 | -70.12 | -67.40 | -79.08 | -29.00 | -32.40 |
| Weighted Avg Shares Out | 1.10M | 544.53K | 380.61K | 242.83K | 129.32K | 117.76K |
| Weighted Avg Shares Out (Dil) | 1.10M | 544.53K | 380.61K | 242.83K | 129.32K | 117.76K |
Kiromic Announces Expansion of In-House Cell therapy cGMP Manufacturing Facility and the Appointment of Industry Veteran Ignacio Núñez as Chief Operating and Manufacturing Officer
KRBP Stock Price: Over 26% Increase Explanation
Kiromic Announces FDA IND Submission First-In-Human, AI derived Off-The-Shelf IsoMesothelin Gamma Delta CAR T-cell Therapy, 30 Days Before the End of the Second Quarter
Kiromic BioPharma Reports First Quarter 2021 Financial Results and Continued Corporate Progress
Kiromic Announces 6 Posters Presented at American Association of Cancer Research 2021 Showcasing our Artificial Intelligence (AI) Biomarker Engine
Kiromic BioPharma Reports Fiscal Year 2020 Financial Results and Continued Corporate Progress
Kiromic BioPharma, Inc. Interview to Air on Bloomberg Television U.S. on the RedChip Money Report
Kiromic to Resubmit Two Expanded INDs to the FDA for Its Allogenic, Off-the-Shelf Gamma-Delta T cell Therapies for Multiple Solid Tumors
Kiromic Announces License Agreement With Longwood University for chPD1
Kiromic Announces the Completion of its GMP Manufacturing Facility in Houston, Texas, to Support the Manufacturing of the First In-Human Allogenic CAR-T Trial
Source: https://incomestatements.info
Category: Stock Reports